MADISON, Wis., Oct. 22, 2023 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced late-breaking data from the pivotal ...

Please provide your email address to receive an email when new articles are posted on . The next-generation Cologuard test was significantly more likely to detect cancer (94% vs. 67%) compared with ...

Sensitivity varied from 10.1 to 36.7%, and specificity varied from 85.5 to 96.6% for advanced colorectal neoplasia. HealthDay News — Fecal immunochemical tests (FITs) have variable sensitivity and ...

The studies reviewed included a variety of designs such as blinded control studies, cross-sectional studies, and cohort studies. The study settings included hospitals and outpatient centers, as well ...

American College of Gastroenterology (ACG) gives BLUE-C study late breaker status at 2023 annual meeting with presentation of the only head-to-head study results versus FIT at ACG High specificity for ...